Abstract library

21 results for "vipoma".
#244 Challenges in the Management of VIPoma Patients
Introduction: VIPomas are a rare neuroendocrine tumor (NET). 90% are pancreatic. 40-70% are metastatic at presentation. The VIPoma syndrome is characterized by secretory diarrhoea, hypokalaemia and achlorhydria.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Fatima El-Khouly
#983 Vipomas: Report of Three Cases in Ten Years
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with an incidence of one in 10 million per year. Most cases arise within the pancreas, with others reported in the lungs, colon, liver, adrenals, and neuroganglia.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Prof. Claudio Pasquali
#1535 VIPomas, a Rare Entity
Introduction: VIP secreting pancreatic neuroendocrine tumors(pNETs) are rare and controlled studies are lacking.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD,PhD Georgios Boutzios
Keywords: VIPoma, pNET
#2110 Pancreatic VIPomas: Reported Cases From China Since 1980
Introduction: Vasoactive intestinal polypeptide (VIP)-secreting tumors (VIPoma) are rare neuroendocrine tumors with distinct clinic presentation.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Chuyan Chen
Authors: Chen C, Zheng Z, Xie Y, Zheng C, ...
Keywords: VIPoma, NET, somatostatin
#2245 Metastatic VIPOMA, Co-Secreting Insulin, with Complete Response to Lanreotide Combined with Capecitabine and Temozolamide
Introduction: VIPomas are rare neuroendocrine tumors (NETs) associated with vasoactive intestinal polypeptide (VIP) hypersecretion causing watery diarrhea, hypokalaemia and achlorhydria. They originate mostly in the pancreas and 60-80% are malignant. Hormonal co-secretion is rarely reported.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Bernardo Marques
#1248 Case Report of Recurrent VIPoma
Introduction: 51yr presented with 7 month diarrhoea&2 stone weight loss. All tests negative, only abnormality hypokalaemia. FGH profile: VIP raised>400, peptide histidine methionine>1000, GAWK of 250. Diagnosis of VIPoma. CT: 5cm mass tail & body of pancreas, no hepatic or adrenal lesions. Octreotide treatment started. Bowel frequency improved, hypokalaemia corrected. Octreotide scan showed uptake only in pancreas. Patient readmitted 5 months later hypokalaemic myopathy, K 1.7, surgical distal pancreatectomy & splenectomy completed. Histology: NET within pancreas, moderate cellular differentiation, variable mitotic rate.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr Victoria Mulcahy
Authors: Mulcahy V, McStay M, Sizer B, ...
Keywords: VIPoma
#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Johann Dréanic
#1106 Salvage Treatment with Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Advanced VIPomas and Severe Verner-Morrison Syndrome
Introduction: PRRT is an effective treatment option for advanced Neuroendocrine Tumours
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT VIP
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#134 Gastrointestinal neuroendocrine tumors: tumor characteristics and long-term clinical outcome in the German NET registry
Introduction: Prognosis of neuroendocrine tumors (NETs) has been difficult to predict due to heterogenous tumor biology, various classification systems, and lack of reliable and recent data due to the rarity of these tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Ulrich-Frank Pape
Authors: Maasberg S, König A, Rinke A, Anlauf M, ...